

Stefanie Hahner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7955096/publications.pdf>

Version: 2024-02-01

146
papers

11,783
citations

28272
55
h-index

28296
105
g-index

160
all docs

160
docs citations

160
times ranked

7337
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e865-e873. | 3.6 | 7 |
| 2 | Adrenal functional imaging. <i>Presse Medicale</i> , 2022, 51, 104114. | 1.9 | 3 |
| 3 | Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using ⁶⁸ Ga-PentixaFor PET. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263693. | 5.0 | 27 |
| 4 | Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT. <i>Molecular Imaging and Biology</i> , 2022, 24, 659-665. | 2.6 | 17 |
| 5 | Primary hyperaldosteronism induces congruent alterations of sodium homeostasis in different skeletal muscles: a 23Na-MRI study. <i>European Journal of Endocrinology</i> , 2022, 186, K33-K38. | 3.7 | 8 |
| 6 | Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1348-e1355. | 3.6 | 5 |
| 7 | CXCR4-targeted theranostics in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4133-4144. | 6.4 | 48 |
| 8 | Non-invasive assessment of tissue sodium content in patients with primary adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2022, 187, 383-390. | 3.7 | 5 |
| 9 | Predictive Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. <i>Hormone and Metabolic Research</i> , 2021, 53, 24-31. | 1.5 | 1 |
| 10 | Therapeutic Patient Education for Adrenal Insufficiency under COVID-19 Pandemic Conditions. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 241-249. | 1.2 | 9 |
| 11 | Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. <i>Endocrine</i> , 2021, 71, 586-594. | 2.3 | 31 |
| 12 | Adrenal insufficiency. <i>Nature Reviews Disease Primers</i> , 2021, 7, 19. | 30.5 | 64 |
| 13 | Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1. | 6.4 | 7 |
| 14 | Management of Patients With Glucocorticoid-Related Diseases and COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 705214. | 3.5 | 15 |
| 15 | Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. <i>European Journal of Endocrinology</i> , 2021, 184, 167-178. | 3.7 | 11 |
| 16 | Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study. <i>BMC Endocrine Disorders</i> , 2021, 21, 11. | 2.2 | 2 |
| 17 | Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma. <i>Cancers</i> , 2021, 13, 5693. | 3.7 | 1 |
| 18 | Glucocorticoid Receptor Polymorphisms Influence Muscle Strength in Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 305-313. | 3.6 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 773-781. | 11.4 | 129 |
| 20 | Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2020, 11, 597878. | 3.5 | 18 |
| 21 | Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2853-e2863. | 3.6 | 30 |
| 22 | Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. <i>Endocrine</i> , 2020, 69, 625-633. | 2.3 | 10 |
| 23 | Standardised patient education in adrenal insufficiency: a prospective multi-centre evaluation. <i>European Journal of Endocrinology</i> , 2020, 183, 119-127. | 3.7 | 18 |
| 24 | A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 188, 38-47. | 2.5 | 4 |
| 25 | An Update on Addison's Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 165-175. | 1.2 | 57 |
| 26 | Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. <i>Annals of Surgical Oncology</i> , 2019, 26, 531-538. | 1.5 | 22 |
| 27 | Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 109-116. | 1.2 | 43 |
| 28 | Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 578-584. | 1.2 | 15 |
| 29 | Increased myocardial sodium signal intensity in Conn's syndrome detected by ²³ Na magnetic resonance imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 263-270. | 1.2 | 32 |
| 30 | Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. <i>Endocrine Connections</i> , 2019, 8, 425-434. | 1.9 | 5 |
| 31 | Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2019, 180, 117-125. | 3.7 | 59 |
| 32 | MON-525 Cardiovascular Status in Chronic Hypoparathyroidism: A Prospective Single-Center Analysis in 143 Patients. <i>Journal of the Endocrine Society</i> , 2019, 3, . | 0.2 | 0 |
| 33 | Management of adrenal emergencies in educated patients with adrenal insufficiency – A prospective study. <i>Clinical Endocrinology</i> , 2018, 89, 22-29. | 2.4 | 31 |
| 34 | Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1686-1695. | 3.6 | 105 |
| 35 | Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. <i>European Journal of Endocrinology</i> , 2018, 178, 605-611. | 3.7 | 26 |
| 36 | Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018, 71, 317-325. | 2.7 | 77 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Acute adrenal crisis and mortality in adrenal insufficiency: Still a concern in 2018!. Annales D'Endocrinologie, 2018, 79, 164-166. | 1.4 | 25 |
| 38 | The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53^{wt} wild type</sup>; Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology, 2018, 106, 1-19. | 2.5 | 25 |
| 39 | Understanding adrenal crisis. Intensive Care Medicine, 2018, 44, 652-655. | 8.2 | 12 |
| 40 | Magnetic resonance cold pressor test to investigate potential endothelial dysfunction in patients suffering from type 1 diabetes. Journal of Magnetic Resonance Imaging, 2018, 48, 1595-1601. | 3.4 | 3 |
| 41 | Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657. | 2.7 | 51 |
| 42 | Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649. | 2.7 | 94 |
| 43 | Surviving ectopic Cushingâ€™s syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushingâ€™s disease during long-term follow-up. European Journal of Endocrinology, 2018, 179, 109-116. | 3.7 | 24 |
| 44 | Management of adrenal emergencies in educated patients with adrenal insufficiencyâ€”A prospective study. , 2018, 89, 22. | | 1 |
| 45 | Immediate versus modified release hydrocortisone in mitotaneâ€”treated patients with adrenocortical cancer. Clinical Endocrinology, 2017, 86, 499-505. | 2.4 | 5 |
| 46 | Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193. | 16.8 | 532 |
| 47 | Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy. Hormone and Metabolic Research, 2017, 49, 208-213. | 1.5 | 11 |
| 48 | Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1358-1365. | 3.6 | 108 |
| 49 | Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. Clinical Nuclear Medicine, 2017, 42, e29-e34. | 1.3 | 60 |
| 50 | Persistence of myopathy in Cushingâ€™s syndrome: evaluation of the German Cushingâ€™s Registry. European Journal of Endocrinology, 2017, 176, 737-746. | 3.7 | 57 |
| 51 | Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, . | 5.0 | 187 |
| 52 | Prevalence of Malignancies in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1656-1663. | 3.6 | 8 |
| 53 | Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine, 2016, 54, 198-205. | 2.3 | 22 |
| 54 | Quality of Life and Life Expectancy in Patients with Adrenal Insufficiency: What Is True and What Is Urban Myth. Frontiers of Hormone Research, 2016, 46, 171-183. | 1.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography. <i>Endocrine</i> , 2016, 53, 791-800. | 2.3 | 8 |
| 56 | 5th International ACC Symposium: Imaging for Diagnosis and Surveillance of Adrenal Tumors—New Advances and Reviews of Old Concepts. <i>Hormones and Cancer</i> , 2016, 7, 40-43. | 4.9 | 6 |
| 57 | Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016, 7, 211-218. | 4.9 | 16 |
| 58 | Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4604-4611. | 3.6 | 19 |
| 59 | Is DHEA replacement beneficial in chronic adrenal failure?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015, 29, 25-32. | 4.7 | 12 |
| 60 | High Incidence of Adrenal Crisis in Educated Patients With Chronic Adrenal Insufficiency: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 407-416. | 3.6 | 308 |
| 61 | Eya4 Induces Hypertrophy via Regulation of p27 ^{kip1} . <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 752-764. | 5.1 | 11 |
| 62 | Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. <i>Annals of Oncology</i> , 2015, 26, 2119-2125. | 1.2 | 196 |
| 63 | Timelines in the management of adrenal crisis – targets, limits and reality. <i>Clinical Endocrinology</i> , 2015, 82, 497-502. | 2.4 | 48 |
| 64 | Diagnosis and management of adrenal insufficiency. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 216-226. | 11.4 | 297 |
| 65 | Timelines in the management of adrenal crisis – targets, limits and reality. , 2015, 82, 497. | | 1 |
| 66 | Outcome of Adrenal Vein Sampling Performed During Concurrent Mineralocorticoid Receptor Antagonist Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4397-4402. | 3.6 | 58 |
| 67 | Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2014, 170, 707-717. | 3.7 | 8 |
| 68 | Saving lives of patients with adrenal insufficiency: a pan-European initiative?. <i>Clinical Endocrinology</i> , 2014, 80, 319-321. | 2.4 | 21 |
| 69 | Suspected metastatic adrenocortical carcinoma revealing as pulmonary Kaposi sarcoma in adrenal Cushing's syndrome. <i>BMC Endocrine Disorders</i> , 2014, 14, 63. | 2.2 | 3 |
| 70 | Saving lives of patients with adrenal insufficiency: a pan-European initiative?. , 2014, 80, 319. | | 1 |
| 71 | Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5 α -Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 161-171. | 3.6 | 131 |
| 72 | Genotype-Phenotype Correlation in 153 Adult Patients With Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency: Analysis of the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E346-E354. | 3.6 | 90 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CT. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1508-1518. | 3.6 | 47 |
| 74 | [123I]Iodometomidate Imaging in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2755-2764. | 3.6 | 45 |
| 75 | [³ H]Metyrapol and 4-[¹³¹ I]Iodometomidate Label Overlapping, but Not Identical, Binding Sites on Rat Adrenal Membranes. Molecular Pharmaceutics, 2013, 10, 1119-1130. | 4.6 | 9 |
| 76 | The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 181-191. | 3.6 | 132 |
| 77 | Assay Characteristics Influence the Aldosterone to Renin Ratio as a Screening Tool for Primary Aldosteronism: Results of the German Conn's Registry. Hormone and Metabolic Research, 2013, 45, 526-531. | 1.5 | 22 |
| 78 | Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). European Journal of Endocrinology, 2013, 168, 887-893. | 3.7 | 67 |
| 79 | Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. European Journal of Endocrinology, 2013, 169, 147-154. | 3.7 | 70 |
| 80 | Tumor Localization in Ectopic Cushing Syndrome Using Combined PET/CT Imaging. Clinical Nuclear Medicine, 2013, 38, 749-751. | 1.3 | 7 |
| 81 | Adrenal Cortical Insufficiency. Deutsches Ärztblatt International, 2013, 110, 882-8. | 0.9 | 47 |
| 82 | Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. European Journal of Endocrinology, 2012, 167, 35-42. | 3.7 | 111 |
| 83 | [131I]Iodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 914-922. | 3.6 | 70 |
| 84 | Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3495-3503. | 3.6 | 146 |
| 85 | <i>TP53</i> Germline Mutations in Adult Patients with Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E476-E485. | 3.6 | 89 |
| 86 | Observational Study Mortality in Treated Primary Aldosteronism. Hypertension, 2012, 60, 618-624. | 2.7 | 235 |
| 87 | Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine, 2012, 366, 2189-2197. | 27.0 | 692 |
| 88 | Dehydroepiandrosterone and androstenedione. , 2012, , 437-458. | | 3 |
| 89 | Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598. | 2.7 | 246 |
| 90 | What is the best long-term management strategy for patients with primary adrenal insufficiency?. Clinical Endocrinology, 2012, 76, 21-25. | 2.4 | 41 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | What is the best long-term management strategy for patients with primary adrenal insufficiency?., 2012, 76, 21. | | 1 |
| 92 | Quality of life is less impaired in adults with congenital adrenal hyperplasia because of 21-hydroxylase deficiency than in patients with primary adrenal insufficiency. Clinical Endocrinology, 2011, 74, 166-173. | 2.4 | 61 |
| 93 | Metomidate-Based Imaging of Adrenal Masses. Hormones and Cancer, 2011, 2, 348-353. | 4.9 | 35 |
| 94 | Addisonian crisis in a young man with atypical anorexia nervosa. Nature Reviews Endocrinology, 2011, 7, 115-121. | 9.6 | 12 |
| 95 | Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3775-3784. | 3.6 | 369 |
| 96 | Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. European Heart Journal, 2011, 32, 1275-1286. | 2.2 | 51 |
| 97 | Delayed Diagnosis of Adrenal Insufficiency Is Common: A Cross-Sectional Study in 216 Patients. American Journal of the Medical Sciences, 2010, 339, 525-531. | 1.1 | 165 |
| 98 | Laparoscopic Versus Open Adrenalectomy for Adrenocortical Carcinoma: Surgical and Oncologic Outcome in 152 Patients. European Urology, 2010, 58, 609-615. | 1.9 | 246 |
| 99 | Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clinical Endocrinology, 2010, 72, 297-304. | 2.4 | 124 |
| 100 | Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology, 2010, 162, 349-356. | 3.7 | 119 |
| 101 | Health Status of Adults with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5110-5121. | 3.6 | 408 |
| 102 | Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. European Journal of Endocrinology, 2010, 162, 597-602. | 3.7 | 274 |
| 103 | Evaluation of a Standardized Protocol for Processing Adrenal Tumor Samples: Preparation for a European Adrenal Tumor Bank. Hormone and Metabolic Research, 2010, 42, 93-101. | 1.5 | 20 |
| 104 | Is Primary Aldosteronism Associated with Diabetes Mellitus? Results of the German Conn's Registry. Hormone and Metabolic Research, 2010, 42, 435-439. | 1.5 | 91 |
| 105 | Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4925-4932. | 3.6 | 150 |
| 106 | Etomidate Unmasks Intraadrenal Regulation of Steroidogenesis and Proliferation in Adrenal Cortical Cell Lines. Hormone and Metabolic Research, 2010, 42, 528-534. | 1.5 | 14 |
| 107 | Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 2010, 23, 1596-1604. | 5.5 | 46 |
| 108 | High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E161-E171. | 3.6 | 196 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Dehydroepiandrosterone to Enhance Physical Performance: Myth and Reality. <i>Endocrinology and Metabolism Clinics of North America</i> , 2010, 39, 127-139. | 3.2 | 13 |
| 110 | Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany. <i>Deutsches A&#x0308;rzteblatt International</i> , 2010, 107, 885-91. | 0.9 | 44 |
| 111 | Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. <i>European Journal of Endocrinology</i> , 2009, 160, 919-924. | 3.7 | 31 |
| 112 | Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Connâ€™s Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1125-1130. | 3.6 | 237 |
| 113 | Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2009, 16, 919-928. | 3.1 | 71 |
| 114 | Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. <i>Endocrine-Related Cancer</i> , 2009, 16, 907-918. | 3.1 | 63 |
| 115 | Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. <i>Cancer</i> , 2009, 115, 243-250. | 4.1 | 597 |
| 116 | Radiotherapy in adrenocortical carcinoma. <i>Cancer</i> , 2009, 115, 2816-2823. | 4.1 | 165 |
| 117 | Osteopontin stimulates invasion of NCIâ€295 cells but is not associated with survival in adrenocortical carcinoma. <i>Journal of Pathology</i> , 2009, 218, 232-240. | 4.5 | 13 |
| 118 | The rs1990760 polymorphism within the IFIH1 locus is not associated with Graves' disease, Hashimoto's thyroiditis and Addison's disease. <i>BMC Medical Genetics</i> , 2009, 10, 126. | 2.1 | 16 |
| 119 | Therapeutic management of adrenal insufficiency. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 167-179. | 4.7 | 49 |
| 120 | The Diagnosis and Treatment of Primary Hyperaldosteronism in Germany. <i>Deutsches A&#x0308;rzteblatt International</i> , 2009, 106, 305-11. | 0.9 | 47 |
| 121 | Insulin gene polymorphisms in type 1 diabetes, Addison's disease and the polyglandular autoimmune syndrome type II. <i>BMC Medical Genetics</i> , 2008, 9, 65. | 2.1 | 10 |
| 122 | New Selective Inhibitors of Steroid 11â²-Hydroxylation in the Adrenal Cortex. Synthesis and Structureâ€™Activity Relationship of Potent Etomidate Analogues. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7652-7652. | 6.4 | 1 |
| 123 | Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2057-2062. | 3.6 | 141 |
| 124 | New Selective Inhibitors of Steroid 11â²-Hydroxylation in the Adrenal Cortex. Synthesis and Structureâ€™Activity Relationship of Potent Etomidate Analogues. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2244-2253. | 6.4 | 45 |
| 125 | Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. <i>European Journal of Endocrinology</i> , 2008, 159, 811-817. | 3.7 | 90 |
| 126 | [123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2358-2365. | 3.6 | 88 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Pituitary-Interrenal Interaction in Zebrafish Interrenal Organ Development. <i>Molecular Endocrinology</i> , 2007, 21, 472-485. | 3.7 | 87 |
| 128 | Impaired Subjective Health Status in 256 Patients with Adrenal Insufficiency on Standard Therapy Based on Cross-Sectional Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3912-3922. | 3.6 | 242 |
| 129 | Do dehydroepiandrosterone supplements have anti-aging potential?. <i>Nature Reviews Urology</i> , 2007, 4, 302-303. | 1.4 | 0 |
| 130 | Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2372-2380. | 27.0 | 679 |
| 131 | DHEA: why, when, and how much – DHEA replacement in adrenal insufficiency. <i>Annales D'Endocrinologie</i> , 2007, 68, 268-273. | 1.4 | 21 |
| 132 | Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. <i>Clinical Endocrinology</i> , 2006, 64, 060222010233001. | 2.4 | 97 |
| 133 | Intraoperative haemodynamic stability in patients with pheochromocytoma ? minimally invasive vs conventional open surgery. <i>Clinical Endocrinology</i> , 2006, 65, 352-358. | 2.4 | 28 |
| 134 | Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4501-4504. | 3.6 | 224 |
| 135 | Adrenocortical Carcinoma - Improving Patient Care by Establishing New Structures. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006, 114, 45-51. | 1.2 | 76 |
| 136 | Evidence against a role of human airway trypsin-like protease – the human analogue of the growth-promoting rat adrenal secretory protease – in adrenal tumourigenesis. <i>European Journal of Endocrinology</i> , 2005, 152, 143-153. | 3.7 | 17 |
| 137 | AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4366-4370. | 3.6 | 43 |
| 138 | Peroxisome Proliferator-Activated Receptor- β Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3886-3896. | 3.6 | 67 |
| 139 | Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained byTPITGene Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1323-1331. | 3.6 | 116 |
| 140 | Management of adrenal insufficiency in different clinical settings. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2407-2417. | 1.8 | 42 |
| 141 | Mitotane for adrenocortical carcinoma treatment. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 386-94. | 2.3 | 90 |
| 142 | The Adrenal Secretory Serine Protease AsP Is a Short Secretory Isoform of the Transmembrane Airway Trypsin-Like Protease. <i>Endocrinology</i> , 2004, 145, 1898-1905. | 2.8 | 30 |
| 143 | Management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2004, 60, 273-287. | 2.4 | 185 |
| 144 | N-Terminal Proopiomelanocortin Acts as a Mitogen in Adrenocortical Tumor Cells and Decreases Adrenal Steroidogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2171-2179. | 3.6 | 64 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Clodronate inhibits adrenocortical cell proliferation and P450c21 activity. Journal of Endocrinology, 2002, 174, 509-516. | 2.6 | 11 |
| 146 | Addisonian crisis in a young man with atypical anorexia nervosa. , 0, . | | 1 |